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Lentiviral vectors (LV) represent a key tool for cell and gene therapy applications. The production of these 
vectors in sufficient quantities for clinical applications remains a hurdle, prompting the field toward developing 
suspension processes that are conducive to large-scale production. Advanced upstream bioprocessing 
approaches will need to be complemented by appropriate downstream processes in order to reduce overall 
manufacturing costs and address the current viral vector supply gap. 
 
In this study, stable HEK293 producer cell lines were employed that grow in suspension, thus offering direct 
scalability, and producing a green fluorescent protein (GFP)-expressing lentiviral vector in the 106-7 transduction 
units (TU)/mL range in batch culture without optimization. HEK293 stable producer cells were retained in 3 L 
bioreactors operated in perfusion mode using either a BioSep acoustic cell filter (Applisens), an XCell™ ATF 
system (Repligen) or a VHU™ Perfusion Filter (Artemis Biosystems). Cultures were grown up to 1 – 1.5 ×106 
cells/mL in batch mode. Perfusion was started at 0.5 volume of medium per reactor volume per day (VVD) and 
induction was carried out after reaching the targeted cell density of 5 ×106 cells/mL. Perfusion was then 
continued at 1 VVD with fresh medium containing inducers for 3 – 4 days. In all perfusion runs, harvests were 
collected and the LV-containing supernatant was kept on ice or at 4ºC until clarification (once daily) and 
subsequently stored at -80ºC until quantification using the GTA assay. We are currently working on bioprocess 
development integrating this upstream process with suitable downstream approaches supported through the 
use of process development-enabling analytical methods. 
 
Our study demonstrates that LV production in perfusion mode using the VHU filter outperformed our routine 
perfusion approach using an acoustic cell filter. Cells were retained in the bioreactor while LV particles passed 
through the filtration device with the harvest. Using this novel device, the cumulative functional LV titers were 
increased by up to 30-fold compared to batch mode, reaching a cumulative total yield of >2 ×1011 TU/L of 
bioreactor culture. This approach is easily amenable to large scale production and commercial manufacturing. 
Purification processes used to manufacture LVs need to be tailored to the unstable nature of LVs to counter 
vector instability and yields need to be improved through process optimization, such as the application of novel 
purification methodologies in continuous or semi-continuous mode. We will describe what DSP strategy we will 
use to most effectively integrate up- and downstream processing for lentiviral vectors. We also expect that our 
bioprocessing strategy will be transferable to other modalities having similar properties than LV. 
 
 
 
 
 
 
